Article Information
History
- December 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Osman N. Yogurtcua,
- Patrick R. Funka,
- Richard A. Forsheea,
- Steven A. Andersona,
- Peter W. Marksb,c and
- Hong Yanga,*
- aOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA
- bOffice of Vaccines Research and Review, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA
- cOffice of the Center Director, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA
- ↵*Correspondence:
Hong.Yang{at}fda.hhs.gov (Office of Biostatistics & Pharmacovigilance, FDA - Center for Biologics Evaluation and Research, 10903 New Hampshire Ave, WO71, Silver Spring, MD 20993-0002 USA)
Posted December 06, 2022.
BENEFIT-RISK ASSESSMENT OF COVID-19 VACCINE, MRNA (MRNA-1273) FOR MALES AGE 18-64 YEARS
